RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Deciphera Pharmaceuticals Stock

Deciphera Pharmaceuticals Equity 2025

Deciphera Pharmaceuticals Equity

350.92 M USD

Ticker

DCPH

ISIN

US24344T1016

WKN

A2H48H

In 2025, Deciphera Pharmaceuticals's equity was 350.92 M USD, a 2.7% increase from the 341.69 M USD equity in the previous year.

Deciphera Pharmaceuticals Aktienanalyse

What does Deciphera Pharmaceuticals do?

Deciphera Pharmaceuticals Inc is a US biopharmaceutical company specializing in the research, development, and marketing of innovative therapeutic solutions for cancer patients. The company was founded in 2003 and is headquartered in Waltham, Massachusetts. Deciphera follows a diversified business model based on multiple pillars. On one hand, the company conducts its own research and development activities to develop new therapy approaches for cancer patients. Deciphera focuses on the research of kinase inhibitors, which offer promising approaches in cancer therapy. On the other hand, the company pursues a licensing strategy by acquiring and further developing already developed active ingredients for cancer therapies in order to make them available to patients. For this purpose, the company collaborates with various partner companies and leading academics and experts in the field of cancer therapy. Deciphera is also engaged in international collaboration through partnerships with local partners in Asia for the research of new cancer therapy approaches. The company invests significant efforts in research and development to constantly adapt its products to the latest scientific advances. Deciphera aims to develop effective and safe therapies for cancer patients that improve their quality of life and increase their chances of survival. The company relies on the research of kinase inhibitors that specifically target certain signaling pathways in cancer cells and thereby inhibit the growth of tumor cells. The company already has a number of products in clinical trials and approval processes that show promising results and are expected to be on the market soon. One promising drug is Ripretinib, dedicated to the cancer type GIST. The goal is to offer a range of cancer medications that have significant treatment success and offer customers high chances of success. Overall, Deciphera Pharmaceuticals is a dynamic and research-oriented company that utilizes the most innovative technologies to give hope to cancer patients and improve the treatment of cancer diseases. With its broad portfolio of active ingredients and therapy approaches, its international presence, and its dedicated research and development, Deciphera Pharmaceuticals Inc. is at the forefront when it comes to innovative cancer treatment therapies. Deciphera Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Deciphera Pharmaceuticals's Equity

Deciphera Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Deciphera Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Deciphera Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Deciphera Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Deciphera Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Deciphera Pharmaceuticals stock

What is the equity of Deciphera Pharmaceuticals this year?

Deciphera Pharmaceuticals has equity of 350.92 M USD this year.

What was the equity of Deciphera Pharmaceuticals compared to the previous year?

The equity of Deciphera Pharmaceuticals has increased/decreased by 2.7% increased compared to the previous year.

What impact does a high equity have on investors of Deciphera Pharmaceuticals?

A high equity is advantageous for investors of Deciphera Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Deciphera Pharmaceuticals?

A low equity can be a risk for investors of Deciphera Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Deciphera Pharmaceuticals affect the company?

An increase in equity of Deciphera Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Deciphera Pharmaceuticals affect the company?

A reduction in equity of Deciphera Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Deciphera Pharmaceuticals?

Some factors that can affect the equity of Deciphera Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Deciphera Pharmaceuticals so important for investors?

The equity of Deciphera Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Deciphera Pharmaceuticals take to change the equity?

To change equity, Deciphera Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Deciphera Pharmaceuticals pay?

Over the past 12 months, Deciphera Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Deciphera Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Deciphera Pharmaceuticals?

The current dividend yield of Deciphera Pharmaceuticals is .

When does Deciphera Pharmaceuticals pay dividends?

Deciphera Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Deciphera Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Deciphera Pharmaceuticals located?

Deciphera Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Deciphera Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Deciphera Pharmaceuticals from 10/8/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/8/2025.

When did Deciphera Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/8/2025.

What was the dividend of Deciphera Pharmaceuticals in the year 2024?

In the year 2024, Deciphera Pharmaceuticals distributed 0 USD as dividends.

In which currency does Deciphera Pharmaceuticals pay out the dividend?

The dividends of Deciphera Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Deciphera Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Deciphera Pharmaceuticals

Our stock analysis for Deciphera Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Deciphera Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.